Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/ β-catenin signal pathway in prostate cancer cells

Bortezomib (BZM), alone or in combination with other chemotherapies, has displayed strong anticancer effects in several cancers. The efficacy of the combination of BZM and mitoxantrone (MTX) in treating prostate cancer remains unknown.